Incident Noninfectious Uveitis Risk after Immune Checkpoint Inhibitor Treatment

Ophthalmology. 2024 Jul;131(7):867-869. doi: 10.1016/j.ophtha.2024.03.017. Epub 2024 Mar 22.

Authors

Myung Soo Chang¹, Seung Won Lee², Sunyeup Kim³, Christopher Seungkyu Lee¹, Suk Ho Byeon¹, Sung Soo Kim¹, Yong Joon Kim⁴

Affiliations

¹ Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea.
² Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Korea.
³ Department of Medical AI, Sungkyunkwan University School of Medicine, Suwon, Korea.
⁴ Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea. Electronic address: kyjcolor@naver.com.

PMID: 38522600
DOI: 10.1016/j.ophtha.2024.03.017

No abstract available

Keywords: immune checkpoint inhibitor; skin melanoma; uveitis.

MeSH terms

Adult
Aged
Female
Humans
Immune Checkpoint Inhibitors* / adverse effects
Incidence
Male
Melanoma / drug therapy
Middle Aged
Retrospective Studies
Risk Factors
Uveitis* / chemically induced
Uveitis* / diagnosis
Uveitis* / drug therapy

Substances

Immune Checkpoint Inhibitors